干扰素联合阿德福韦酯治疗对拉米夫定耐药的乙型肝炎患者临床效果分析
发布时间：2018-12-06 09:08
【摘要】：目的探讨干扰素联合阿德福韦酯治疗对拉米夫定耐药乙型肝炎患者的临床效果,为临床效果提供理论指导与依据。方法选取2011年2月-2013年2月于医院接受治疗的90例对拉米夫定耐药乙型肝炎患者作为研究对象,随机平均分为对照组和观察组,各45例;对照组患者应用阿德福韦酯进行治疗,观察组患者应用干扰素联合阿德福韦酯进行治疗;比较两组患者治疗12个月后的临床指标,数据采用SPSS 10.0软件进行统计分析。结果对照组患者治疗前后丙氨酸氨基转移酶、HBV-DNA与观察组比较,差异均无统计学意义;对照组患者的HBsAg和HBeAg阴转率分别为0和42.86%,观察组患者的HBsAg和HBeAg阴转率分别为9.38%和91.67%,观察组患者的阴转率显著高于对照组的,差异有统计学意义(P0.05)。结论两组治疗方法对患者均起到了治疗的作用,联合治疗比单使用阿德福韦酯治疗的效果更好,能更好、更快提高患者HBeAg和HBsAg的阴转率。
[Abstract]:Objective to investigate the clinical effect of interferon combined with adefovir in lamivudine resistant hepatitis B patients, and to provide theoretical guidance and basis for clinical effect. Methods from February 2011 to February 2013, 90 patients with lamivudine resistant hepatitis B were randomly divided into control group and observation group. The patients in the control group were treated with adefovir ester, the patients in the observation group were treated with interferon and adefovir ester, and the clinical indexes of the two groups were compared after 12 months of treatment. The data were analyzed by SPSS 10.0 software. Results there was no significant difference in alanine aminotransferase and HBV-DNA between the control group and the observation group before and after treatment. The negative conversion rates of HBsAg and HBeAg were 0 and 42.86 in the control group, and 9.38% and 91.67% in the observation group, respectively. The negative conversion rate of the observation group was significantly higher than that of the control group. The difference was statistically significant (P0.05). Conclusion both the two groups have a therapeutic effect on the patients. The combined treatment is better and better than that of adefovir alone, and the negative conversion rate of HBeAg and HBsAg can be increased more quickly than that of adefovir alone.
【作者单位】： 宁夏人民医院感染病科;陕西医科大学附属第一医院;
【基金】：宁夏自然科学基金资助项目(NZ1271)
【分类号】：R512.62
，
本文编号：2365797
[Abstract]:Objective to investigate the clinical effect of interferon combined with adefovir in lamivudine resistant hepatitis B patients, and to provide theoretical guidance and basis for clinical effect. Methods from February 2011 to February 2013, 90 patients with lamivudine resistant hepatitis B were randomly divided into control group and observation group. The patients in the control group were treated with adefovir ester, the patients in the observation group were treated with interferon and adefovir ester, and the clinical indexes of the two groups were compared after 12 months of treatment. The data were analyzed by SPSS 10.0 software. Results there was no significant difference in alanine aminotransferase and HBV-DNA between the control group and the observation group before and after treatment. The negative conversion rates of HBsAg and HBeAg were 0 and 42.86 in the control group, and 9.38% and 91.67% in the observation group, respectively. The negative conversion rate of the observation group was significantly higher than that of the control group. The difference was statistically significant (P0.05). Conclusion both the two groups have a therapeutic effect on the patients. The combined treatment is better and better than that of adefovir alone, and the negative conversion rate of HBeAg and HBsAg can be increased more quickly than that of adefovir alone.
【作者单位】： 宁夏人民医院感染病科;陕西医科大学附属第一医院;
【基金】：宁夏自然科学基金资助项目(NZ1271)
【分类号】：R512.62
，
本文编号：2365797
本文链接：https://www.wllwen.com/yixuelunwen/xiaohjib/2365797.html
最近更新
教材专著
